Rheumatology (Oxford, England)
Authors: Maguire S, Al-Emadi S, Alba P, Aguiar MC, Lawati TA, Alle G, Bermas B, Bhana S, Branimir A, Bulina I, Clowse M, Cogo K, Colunga I, Cook C, Cortez KJ, Dao K, Gianfrancesco M, Gore-Massey M, Gossec L, Grainger R, Hausman J, Hsu TYT, Hyrich K, Isnardi C, Kawano Y, Kilding R, Kusevich DA, Lawson-Tovey S, Liew J, McCarthy E, Montgumery A, Moyano S, Nasir N, Padjen I, Papagoras C, Patel NJ, Pera M, Pisoni C, Pons-Estel G, Quiambao AL, Quintana R, Ruderman E, Sattui S, Savio V, Sciascia S, Sencarova M, Morales RS, Siddique F, Sirotich E, Sparks J, Strangfeld A, Sufka P, Tanner H, Tissera Y, Wallace Z, Werner ML, Wise L, Worthing AB, Zell J, Zepa J, Machado PM, Yazdany J, Robinson P, Conway R, COVID-19 Global Rheumatology Alliance
Critical care (London, England)
Authors: Wick KD, Leligdowicz A, Willmore A, Carrillo SA, Ghale R, Jauregui A, Chak SS, Nguyen V, Lee D, Jones C, Dewar R, Lane HC, Kangelaris KN, Hendrickson CM, Liu KD, Sinha P, Erle DJ, Langelier CR, Krummell MF, Woodruff PG, Calfee CS, Matthay MA, COMET Consortium
JMIR human factors
Authors: Liu AW, Odisho AY, Brown Iii W, Gonzales R, Neinstein AB, Judson TJ
The Journal of infectious diseases
Authors: Peluso MJ, Mitchell A, Wang CY, Takahashi S, Hoh R, Tai V, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Wilson MR, Greenhouse B, Deeks SG, DeRisi JL, Henrich TJ
Musculoskeletal care
Authors: Hulen E, Larsen C, Matsumoto R, Katz P, Barton JL
Journal of addiction medicine
Authors: Riley ED, Warner L, Hahn JA, Braun C, Dilworth S, Zevin B, Neilands TB, Weiser SD
Volume 14 of Issue 17 | Cancers
Authors: Wagner MJ, Hennessy C, Beeghly A, French B, Shah DP, Croessmann S, Vilar-Compte D, Ruiz-Garcia E, Ingham M, Schwartz GK, Painter CA, Chugh R, Fecher L, Park C, Zamulko O, Trent JC, Subbiah V, Khaki AR, Tachiki L, Nakasone ES, Loggers ET, Labaki C, Saliby RM, McKay RR, Ajmera A, Griffiths EA, Puzanov I, Tap WD, Hwang C, Tejwani S, Jhawar SR, Hayes-Lattin B, Wulff-Burchfield E, Kasi A, Reuben DY, Nagaraj G, Joshi M, Polimera H, Kulkarni AA, Esfahani K, Kwon DH, Paoluzzi L, Bilen MA, Durbin EB, Grivas P, Warner JL, Davis EJ, COVID-19 and Cancer Consortium
BACKGROUND
Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.
METHODS
We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.
RESULTS
of 281 patients, 49% ( = 139) were hospitalized, 33% ( = 93) received supplemental oxygen, 11% ( = 31) were admitted to the ICU, and 6% ( = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity.
CONCLUSIONS
Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.
View on PubMed
The Lancet. Respiratory medicine
Authors: Conrad C, Looney MR
Journal of obesity & metabolic syndrome
Authors: Collins WJ, Chang AY, Weng Y, Dahlen A, O'Brien CG, Hom J, Ahuja N, Rodriguez F, Rohatgi N
Journal of women's health (2002)
Authors: Roubinov D, Haack LM, Folk JB, Rotenstein L, Accurso EC, Dahiya P, Ponce AN, Nava V, Maldonado Y, Linos E, Mangurian C
